RPAM
VERA icon

Rhenman & Partners Asset Management’s Vera Therapeutics VERA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-420,000
Closed -$21.3M – 103
2025
Q4 		$21.3M Buy
420,000
+290,000
+223% +$10.3M 1.99% 12
2025
Q3 		$3.78M Buy
+130,000
New +$3.01M 0.42% 64

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Rhenman & Partners Asset Management's VERA Position: Q1 2026 in Review

Rhenman & Partners Asset Management sold out of Vera Therapeutics (VERA) in Q1 2026, closing a stake of 420,000 shares — an estimated $21.3M sold.

Rhenman & Partners Asset Management first reported a position in VERA in Q3 2025 and held it in 2 quarters. The position peaked at $21.3M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Rhenman & Partners Asset Management reported no remaining Vera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 420,000 Vera Therapeutics shares in Q1 2026, an estimated $21.3M.
  • Rhenman & Partners Asset Management first reported a position in Vera Therapeutics in Q3 2025 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Vera Therapeutics position peaked at $21.3M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.